featured
Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
JAMA Neurol 2021 Jul 01;78(7)834-841, JR Mendell, SA Al-Zaidy, KJ Lehman, M McColly, LP Lowes, LN Alfano, NF Reash, MA Iammarino, KR Church, A Kleyn, MN Meriggioli, R ShellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.